Status:
RECRUITING
Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form
Lead Sponsor:
University Hospital, Brest
Conditions:
Asthma in Children
Dysbiosis
Eligibility:
All Genders
1-3 years
Phase:
NA
Brief Summary
The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. R...
Detailed Description
The prevalence of asthma in preschool children is estimated to between 11 and 12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in so...
Eligibility Criteria
Inclusion
- Age greater than 1 year and less than 3 years
- Diagnosis of asthma by a pediatrician
- Parental consent
- Affiliation to the social security system
Exclusion
- Chronic pathologies: congenital heart disease, immune deficiency, cystic fibrosis, bronchopulmonary dysplasia, encephalopathy, primary ciliary dyskinesia, laryngomalacia, digestive pathology requiring digestive surgery
- Premature \< 34 SA
- Recent antibiotic therapy (\< 7 days)
- Treatment with oral corticosteroid therapy within the previous 10 days.
- Patient whose parent(s) is (are) minor(s)
Key Trial Info
Start Date :
February 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 4 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05192499
Start Date
February 4 2022
End Date
February 4 2028
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest
Brest, Finistère, France, 29609